Recursion Pharmaceuticals announced positive Phase 2 data for its drug REC-4881 in treating familial adenomatous polyposis (FAP), showing significant reductions in polyp burden. This positive clinical trial outcome is a significant de-risking event for the drug and the company, potentially leading to a registrational trial in 2027.
Recursion Pharmaceuticals reported positive Phase 2 data for REC-4881, an oral MEK1/2 inhibitor, in patients with familial adenomatous polyposis (FAP). The data showed deep and durable reductions in polyp burden, with 47% of patients achieving a median reduction after 12 weeks. This is a significant positive development for Recursion (RXRX) as it de-risks the drug's development pathway and supports the company's plan to initiate a registrational trial in the second half of 2027. For traders, this news presents a short-term positive catalyst for RXRX stock due to improved clinical prospects, with long-term implications tied to successful registrational trials and eventual market approval. The key opportunity is the potential for REC-4881 to become a significant treatment option for FAP, a rare genetic disorder.